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Conformational diseasesAmyloidoses are devastating diseases characterized by accumulation of misfolded proteins which aggregate in
ﬁbrils. Speciﬁc gene mutations in Apolipoprotein A I (ApoAI) are associated with systemic amyloidoses. Little is
known on the effect of mutations on ApoAI structure and amyloid properties. Here we performed a physico-
chemical characterization of L75P- and L174S-amyloidogenic ApoAI (AApoAI) variants to shed light on the effects
of two single point mutations on protein stability, proteolytic susceptibility and aggregation propensity. Both var-
iants are destabilized in their N-terminal region and generate ﬁbrils with different morphological features. L75P-
AApoAI is signiﬁcantly altered in its conformation and compactness, whereas a more ﬂexible and pronounced
aggregation-competent state is associated to L174S-AApoAI. These observations point out how single point mu-
tations in ApoAI gene evocate differences in the physico-chemical and conformational behavior of the corre-
sponding protein variants, with the common feature of diverting ApoAI from its natural role towards a
pathogenic pathway.
© 2015 Elsevier B.V. All rights reserved.1. Background
Amyloidoses are characterized by protein aggregation in insoluble
ﬁbrils and their deposition in tissues and organs, with consequent alter-
ation of their functionality. To date, almost 30 amyloidogenic proteins
have been identiﬁed [1]; although these proteins do not show any se-
quence or structure homology, they have the ability to give rise to am-
yloid ﬁbrils characterized by a highly ordered and rigid structure [2–5].
Apolipoprotein A I (ApoAI) is themain component of high density li-
poproteins (HDL) and is mostly involved in the removal of cholesterol
from peripheral tissues and its transfer, via the plasma, to the liver,
where it is either recycled back to plasma as a component of newlycid; ApoAI, apolipoprotein A I;
hroism; DLS, dynamic light scat-
ity lipoproteins; MD, molecular
ic forcemicroscopy; LC-MS, liq-
Sciences, University of Naplesformed lipoproteins, or excreted from the body via bile [6]. Due to
ApoAI conformational plasticity, in its lipid-free or lipid-poor form,
this protein is able to bind to phospholipids and to unesteriﬁed choles-
terol to give rise to nascent HDL [7].
Some of the mutations in ApoAI gene are associated with hereditary
systemic amyloidoses, characterized by extracellular ﬁbrillar deposits in
speciﬁc tissues, mainly heart, liver, kidneys and testes [8–10]. It has
been reported that in the HDLs of heterozygous patients, in which both
the wild-type protein and an amyloidogenic variant (L75P-AApoAI,
L174S-AApoAI or L64P-AApoAI) are present, the wild-type protein is
more abundant than the variant [11–13]. This ﬁnding is in line with
our recent observation that in stably transfected human hepatic cells
over-expressing L75P-AApoAI the secretion of the amyloidogenic variant
is down-regulated [14], which in turn is in line with the observation of
Marchesi and coworkers, who reported a decreased secretion efﬁciency
of L75P- and L174S-AApoAI variants in transiently transfected COS cells
[15]. Moreover, it has been hypothesized that AApoAI variants have a
lower afﬁnity for HDLs when compared to the wild-type protein; this
would shift the ApoAI distribution from HDL-bound to lipid-poor/free
state, which is relatively unstable and susceptible to proteolysis. The
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ApoAI revealed that ApoAI associates in domain swappeddimers held to-
gether by two four-helix bundles each constituted by the N-terminus of
one subunit and the C-terminus of its partner. Interestingly, all the 19
amyloidogenic mutations so far identiﬁed cluster in two regions: the
amino-terminus (residues 1–100) and within residues 173–178 [16],
which, in the dimeric structure, deﬁne a 3D hot-spot mutation site [17].
To date, only few full-length AApoAI variants, out of 19 identiﬁed so
far, have been investigated, which show signiﬁcant peculiarities on the
conformational transitions [18–21]. Recently, a model has been pro-
posed, prompting that AApoAI mutations perturb one of the 4 predicted
hot spots of the protein (14–22, 53–58, 69–72 and 227–232), with con-
sequent full-length protein aggregation via the N-terminal region. This
event would be followed by proteolytic cleavage at the exposed loop
(83–100) and release of the N-terminal ﬁbrillogenic polypeptide [21],
which has been found to be the main protein constituent of ex-vivo ﬁ-
brils [8]. It has been hypothesized that perturbation in the hot spots is
one of the prerequisite for AApoAI misfolding, even though other factors
may inﬂuence this process [21]. Here we analyzed the effects of two
point mutations, L75P and L174S, on AApoAI conformational stability,
being the former an “inside” mutation, i.e. located within the N-
terminal ﬁbrillogenic polypeptide, and the latter an “outside” mutation.
Leu 75 is located in the middle of the short helix 70–76 that contributes
to deﬁne the relative helical orientation in the four-segment bundle,
whereas Leu 174 is located in the “bottom” of the hydrophobic cluster
[22]. The variant with leucine to proline substitution at position 75
(L75P-AApoAI) is associated with a hereditary systemic amyloidosis
characterized by preferential accumulation of ﬁbrils in the kidneys and
liver [11]. Instead, in the case of leucine to serine substitution at position
174 (L174S-AApoAI), a predominant accumulation of ﬁbrils in the heart,
skin, testes and larynxwas observed [12]. Themolecular basis of this dif-
ferential localization of amyloid ﬁbrils is still unknown.
We report structural stability, proteolytic susceptibility and aggrega-
tion propensity of full-length recombinant, lipid-free, human AApoAI
harboring L75P or L174S mutation, to reveal the effects of a single
point mutation on AApoAI structure and amyloidogenic potential.
This study is aimed to add knowledge to the largely unknown ﬁeld of
systemic amyloidoses. Starting from the general hypothesis suggesting
that single point mutations, occurring in the 3D hot spot mutation
site, direct the protein towards an amyloidogenic pathway, our study
is aimed at revealing common and different impacts of mutations on
protein stability.
2. Methods
2.1. Production of recombinant proteins
A bacterial expression system consisting of ApoAI expressing pET20
plasmid in Escherichia coli strain BL21(DE3) pLysS (Invitrogen) was
used to prepare AApoAI proteins, as previously described [18]. Primer-
directed PCR mutagenesis was used to introduce the L75P and L174S
mutations. The mutation was veriﬁed by dideoxy automated ﬂuores-
cent sequencing. Human ApoAI proteins were puriﬁed from bacterial
cell lysate by immobilized metal afﬁnity chromatography (HiTrap col-
umns, GE Healthcare, Waukesha, WI) under denaturing conditions
(4 M urea). Following binding, an extensive wash with 500 mM NaCl
and 4M urea in sodium phosphate buffer, 20mM, pH 7.4 (wash buffer)
was performed and bound proteins were then eluted with 500 mM im-
idazole in wash buffer. Proteins were dialyzed versus refolding buffer
(50 mM Tris–HCl, pH 7.4), concentrated with 30 kDa molecular weight
cut-off Amicon Ultra centrifugal ﬁlter devices (Millipore), and stored at
−20 °C.
Purity and identity of the wild-type and variants were conﬁrmed by
LC–MS analyses, as reported below. Chromatographic traces recorded
for each protein preparation, showed a single sharp peak, correspond-
ing to the recombinant protein and the measured molecular masseswere in agreement with the theoretical ones, according to the amino
acid sequences of his-tagged expressed constructs (wild-type ApoAI:
measured molecular mass: 29,799.6 ± 1.1 Da, theoretical molecular
mass: 29,798.5 Da; L75P-AApoAI: measured molecular mass:
29,783.0 ± 1.8 Da, theoretical molecular mass: 29,782.5 Da; L174S-
AApoAI: measured molecular mass: 29,772.8 ± 1.5 Da, theoretical mo-
lecular mass: 29,772.4 Da). For all the experiments His-tag containing
proteins were used, as in preliminary conformational analyses (data
not shown) we did not observe any signiﬁcant difference comparing
the His-tag containing wild-type protein to the protein after His-tag re-
moval, or to commercial ApoAI (Sigma-Aldrich).
2.2. CD spectroscopy
Circular dichroism (CD) measurements were performed on a Jasco
J815 spectropolarimeter (Jasco, Essex, UK), equipped with a tempera-
ture control system, using a 1-mm quartz cell in the far-UV range
194–260 nm (50 nm/min scan speed). Each spectrum was the average
of three scans with the background of the buffer solution subtracted.
Measurements were performed at 25 °C at a protein concentration of
0.15 mg/mL in 50 mM Tris HCl pH 7.4. Raw spectra were corrected for
buffer contribution and converted to mean residue ellipticity, θ
(mdeg cm2 dmol−1). Estimation of the secondary structure was carried
out according to the Variable Selection Method (CDSSTR) using
DICHROWEB [23].
2.3. Intrinsic ﬂuorescence analysis
Emission ﬂuorescence spectra were recorded in the range 300–
450 nm, following excitation at 280 (tyrosine/tryptophan) or 295 nm
(tryptophan). Measurements were carried out at 25 °C in a 10 mm cell
by using a Perkin-Elmer LS50 spectroﬂuorimeter. Emission spectra
were acquired at a scanning speed of 300 nm/min, with 10 and 5 slit
widths for excitation and emission, respectively. Proteins (3 μM) were
analyzed in 50 mM Tris HCl at pH 7.4.
2.4. Dye-binding assays
2.4.1. ThT binding assay
Proteins (0.3 mg/mL) were incubated at 25 °C in 50 mM Tris HCl at
pH 7.4 in the presence of 10 μM thioﬂavin T (ThT). ThT ﬂuouorescence
emission spectra were acquired in the range 470–490 nm at 1 h intervals
with scan speed of 300 nm/min, upon excitation at 450 nm. Excitation
and emission slits were set at 5 and 10 nm, respectively. Fluorescence in-
tensity values at 482 nmwere plotted as a function of time. The determi-
nation of apparent t1/2 valueswas obtained by non-linear regression ﬁt of
the data according to a double Boltzmann equation. The reported values
represent the means from three independent experiments.
2.4.2. 1-Anilinonaphthalene-8-sulfonic acid (ANS) binding assay
Emission ﬂuorescence spectra of recombinant proteins (3 μM) were
acquired in the presence of the dye ANS (350 μM). Analyses were per-
formed in 50 mM Tris HCl at pH 7.4, at 25 °C. Emission ﬂuorescence
spectra were recorded in the range 400–600 nm, following excitation
at 380 nm. Excitation and emission slits were set at 5 and 10 nm,
respectively.
2.5. Protein stability to denaturing agents
2.5.1. Chemical denaturation
Equilibrium denaturation was carried out on samples using guani-
dine (GdnHCl) and urea. Proteins were incubated for 24 h at 4 °C at
0.05 mg/mL prior to addition of denaturant. Incubated proteins were
combined with denaturant, diluted from 8 M stock solutions. Samples
were stored at 4 °C for 24 h prior to data collection. Changes in trypto-
phan ﬂuorescence were recorded. The unfolding transition was
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tensity (λmax). The λmax of triplicate dilutions of each sample was aver-
aged and plotted against the denaturant concentration. Experimental
points, describing sigmoidal curves, were ﬁtted using the Boltzmann
equation andD1/2 (the concentration of denaturant atwhich the protein
is half folded) was calculated. Assuming a two-state model (folded and
unfolded), the free energy of denaturation was calculated as described
by Petrlova et al. [18] by using the equation: ΔGD° =−RTlnKD. ΔGD°
andm values were obtained by plottingΔGD versus denaturant concen-
tration to give the linear equation [24] ΔGD = ΔGD°−m[denaturant],
where ΔGD° is the free energy of protein folding in water (0M denatur-
ant), and m the cooperativity of denaturation.
2.5.2. Thermal denaturation
Temperature-induced denaturation of proteins (0.05 mg/mL) was
performed as a function of increasing temperature (20–100 °C). Protein
samples were incubated at the desired temperature for 15 min before
taking the measurements. Denaturation of proteins was performed by
recording changes in tryptophan ﬂuorescence.
2.6. Homology modeling and molecular dynamics simulations
The starting structure of wild-type ApoAI for molecular dynamics
simulation was taken from the protein data bank (PDB) ﬁle 3R2P [17].
The structure, which has been solved at 2.2 Ǻ resolution, includes resi-
dues 3–182 of two chains. Based on the evidence of dynamic light scat-
tering experiments, this dimeric structure was considered as
representative of the protein conformation in solution. Models of the
mutants were built on the structure of wild-type ApoAI by manual res-
idue replacement.
Molecular dynamics (MD) and trajectory analysis were performed
with the software package GROMACS 4.6.6 [25–27] using the
Gromos43a1 force ﬁeld. Appropriate number of counterions (Na+)
was added to neutralize the systems. The structures were immersed in
a rectangular box ﬁlled with SPC water molecules at a density of
1000 kg/m3 [28] with periodic boundary conditions. Long-range elec-
trostatic interactions were treated with the particle-mesh Ewald meth-
odwith a grid spacing of 12 Å and cutoff of 8 Å. [29]. Themoleculeswere
submitted to initial energy minimisation with the steepest descent for
5000 steps followed by 500 ns NVT and 500 ps NPT equilibration with
position restraints. Production runs were performed for 10 ns with a
2 fs step. To the best of our knowledge, these simulations are the ﬁrst
ever performed on mutants of ApoAI.
Temperature and pressure coupling were obtained with the v-rescale
[30] and the Parrinello-Rahman [31] algorithms, respectively. Bond
lengths were constrained using LINCS [32]. The overall ﬂexibility of the
systems was evaluated comparing the traces obtained by diagonalizing
the covariance matrix of the coordinate ﬂuctuations, as previously de-
scribed [33]. Only Cα atomswere included in the deﬁnition of the covari-
ance matrices. Figures were prepared with Pymol (www.pymol.org).
2.7. Complementary proteolysis experiments and mass
spectrometry analysis
Complementary proteolysis experiments were carried out by
treating 0.4 mg/mL solutions of proteins with trypsin, chymotrypsin,
and endoproteinase Glu-C in 50mMTris HCl, pH 7.4. Different E:S ratios
were optimized for each proteolytic probe as reported: 1:8000 for chy-
motrypsin and trypsin, 1:10,000 for endoprotease Glu-C. The extent of
digestion was monitored on a time-course basis by sampling the reac-
tion mixture at 15 and 30 min and blocking the reactions with 2%
triﬂuoroacetic acid (TFA). Peptide mixtures were analyzed by liquid
chromatography-mass spectrometry (LC–MS) onto a QuattroMicro LC-
MS system (Micromass, Waters) interfaced with a 1100 HPLC (Agilent
Technologies, Palo Alto, CA). Peptide mixtures from the different prote-
olysis experiments were fractionated by reverse-phase HPLC on aPhenomenex Jupiter C18 column (250 mm × 2.1 mm, 300 Å pore
size) and eluted by using a step gradient from 5% to 60% of solvent B
(5% formic acid and 0.05% TFA in acetonitrile) over 60 min and from
60% to 95% in 5 min (solvent A 5% formic acid and 0.05% TFA in
water). The ﬂow rate was kept at 200 μL/min and directly introduced
in the mass spectrometers ESI source. Horse heart myoglobin was
used to calibrate the instrument (average molecular mass
16,951.5 Da) at 5 scans/s.2.8. Determination of critical concentration
Proteins were incubated at different concentrations (from 0.15 to
2 mg/mL) in 50 mM Tris HCl pH 7.4 for 14 days at 37 °C. Then, sam-
ples were centrifuged at 14,000 g for 30 min at r.t., supernatants
were ﬁltered with a 20 nm cut off ﬁlter and the absorbance at
280 nm measured.2.9. Dynamic light scattering
Dynamic light scattering (DLS) measurements were carried out using
aMalvern nano zetasizer (Malvern, UK) [34]. Proteins (0.55mg/mL)were
diluted in 50 mM Tris HCl at pH 7.4, ﬁltered with a 0.22 μm cut off ﬁlter
and incubated at 37 °C over time. Sampleswere placed in a disposable cu-
vette and held at 25 °C during analysis. The aggregation rate was moni-
tored at time 0 and after 24 h, 48 h and 7 days of incubation. For each
sample, spectra were recorded six times with 11 sub-runs using themul-
timodal mode. The Z average diameter was calculated from the correla-
tion function using the Malvern technology software.2.10. Atomic force microscopy
For AFM inspection, ApoAI samples were incubated at 0.3 mg/mL at
37 °C. Incubation times in the range from 4 to 7weekswere considered.
At the end of incubation, proteinswere centrifuged at 1700 g for 10min,
the pellet was suspended in an equal volume of water, and a 10 μL ali-
quot was deposited on freshly cleavedmica and dried under mild vacu-
um. Tappingmode AFM images were acquired in air using aMultimode
SPM, equippedwith “E” scanning head (maximum scan size 10 μm) and
driven by a Nanoscope V controller, and a Dimension 3100 SPM,
equipped with a ‘G’ scanning head (maximum scan size 100 μm) and
driven by a Nanoscope IIIa controller (Digital Instruments, Bruker AXS
GmbH, Karlsruhe, Germany). Single beam uncoated silicon cantilevers
(typeOMCL-AC160TS, Olympus, Tokyo, Japan)were used. The drive fre-
quency was between 290 and 340 kHz, the scan rate was between 0.3
and 0.8 Hz. Aggregate sizes were estimated from the heights in cross
section of the topographic AFM images.3. Results
3.1. Effects of amyloidogenic mutations on ApoAI secondary structure
The secondary structure content of AApoAI variants was estimated
by far-UV CD spectroscopy at pH 7.4, at 0.15 mg/mL protein concentra-
tion to approximate physiological conditions. As shown in Fig. 1, wild-
type ApoAI and the two amyloidogenic variant proteins were predomi-
nantly in anα-helical state, with a slightly lower α-helix content of the
variants with respect to the wild-type protein (Table 1). When the pro-
teins were incubated at 37 °C over time, no signiﬁcant changes in the
spectra of the wild-type protein were observed, consistently with liter-
ature data [18 and references therein]; on the contrary, theα-helicity of
both variants decreased over time accompanied by an increase in β-
strand, indicating an alteration of the protein native conformation to-
wards an aggregation competent state.
Fig. 1. Far-UV CD spectra of wild-type ApoAI and its amyloidogenic variants upon incuba-
tion at 37 °C. A,wild-type ApoAI; B, L75P-AApoAI; C, L174S-AApoAI. Spectrawere acquired
at 25 °C with 0.15 mg/mL protein concentration in 50 mM TrisHCl buffer, pH 7.4. Spectra
were recorded at time 0 (bold black line), after 24 h (black dashed line), 48 h (gray dashed
line), 72 h (black ﬁne line) and after 7 days (bold gray line) incubation.
Table 1
α-Helix andβ-strand contents (%) forwild-type ApoAI and its amyloidogenic variants, up-
on incubation at 37 °C. Data shown are the means from three independent experiments.
The accuracy of the secondary structure content estimation is approximately 2% for
wild-type ApoAI and 4% for its amyloidogenic variants.
Incubation
time (h)
Wild-type ApoAI L75P-AApoAI L174S-AApoAI
α-Helix
(%)
β-Strand
(%)
α-Helix
(%)
β-Strand
(%)
α-Helix
(%)
β-Strand
(%)
0 49 29 40 36 45 28
24 49 28 34 36 40 21
48 47 29 32 39 35 37
72 40 34 31 39 29 41
168 38 33 29 40 20 53
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During amyloid formation protein aggregation leads to an increase
in the exposure of hydrophobic regions to the aqueous environment.
ANS binding studies revealed a 3-fold increase of ANS ﬂuorescence in-
tensity in the presence of wild-type ApoAI (Fig. 2A, black line), due to
the exposure of ANS accessible hydrophobic surfaces, as previously re-
ported [35–38]. A larger increase of ANS ﬂuorescence was measured
for both variants compared to wild-type ApoAI, particularly evident
for L174S-AApoAI variant, indicating that bothmutations trigger the ex-
posure of hydrophobic regions (Fig. 2A, gray line and dashed line for
L75P-AApoAI and L174S-AApoAI, respectively).
To compare the tertiary structure of AApoAI variants with that of the
wild-type protein, the intrinsic ﬂuorescence emission intensitywas reg-
istered and the shift of maximum emission wavelength (λmax), due to
changes in solvent exposure of tyrosine and tryptophan residues, was
evaluated. As the four Trp residues of thewild-type protein (at positions
8, 50, 72 and 108), as well as the ﬁve Tyr residues (at positions 18, 29,
100, 115, 166), are located within the four-helix bundle domain and
are all conserved in the amyloidogenic variants under study, this analy-
sis is a measure of the stability of AApoAI N-terminal region. Fluores-
cence spectra were collected either upon excitation at 295 nm, where
the contribution of tyrosine residues is negligible (Fig. 2B), or upon ex-
citation at 280 nm, where both Tyr and Trp residues signiﬁcantly con-
tribute to the absorption (Fig. 2C). As shown in Fig. 2B, in the case of
L75P-AApoAI (gray line) themaximum ﬂuorescence intensity emission
wavelength (λmax = 344.7 ± 0.3 nm) is higher than that of wild-type
ApoAI (λmax = 335.7 ± 0.6 nm). These data suggest that the substitu-
tion L75P is able to induce changes in the conformation of the N-
terminal domain with consequent exposure of hydrophobic protein
surfaces, since proline is known to interrupt proteinα-helical structure.
On the contrary, L174S-AApoAI (Fig. 2B, dashed line) showed a λmax =
336.3 ± 1.2 nm, a value similar to that recorded for wild-type ApoAI.
Similar results were observed when the contribution of both Tyr and
Trp was analyzed (Fig. 2C and Table S1).3.3. Effects of mutations on ApoAI stability
To get insights into the structural features that favor AApoAI
amyloidogenicity, we compared the folding of the L75P-AApoAI and
L174S-AApoAI to that of wild-type ApoAI by investigating protein sta-
bility in the presence of chemical denaturing agents, such as guanidine
hydrochloride (GdnHCl) and urea. Upon excitation at 295 nm, the
unfolding transition was monitored by evaluating the change in λmax
as a function of chemical agent concentration. As the equilibrium
unfolding of wild-type ApoAI by GdnHCl has been well characterized,
it can be used as a reference for the stability of the variants. As shown
in Fig. 3(A–B), sigmoidal curves (ﬁlled squares) were obtained in the
case of wild-type protein, conﬁrming a cooperative unfolding pattern
that well ﬁts the two-state model [18,39]. As shown in Table 2, the
mid-point of the denaturation process (D1/2 values), ΔGD° and
Fig. 2. Fluorescence analyses of AApoAI variants. A, binding of ANS to wild-type ApoAI
(black line) and to its amyloidogenic variants L75P (gray line) and L174S (dashed line).
ANS spectrum is reported as a ﬁne black line. ANS emission ﬂuorescence spectra were re-
corded in the range from 400 to 600 nm at the excitation wavelength of 395 nm. ANS
emission was monitored at pH 7.4. B and C, tryptophan and tyrosine emission spectra at
pH 7.4 of wild-type ApoAI (bold black line), L75P-AApoAI (gray line) and L174S-AApoAI
(dashed line). Fluorescence was excited at 295 nm (B) and at 280 nm (C).
Fig. 3.Unfoldingofwild-typeApoAI (ﬁlled squares) and of its amyloidogenic variants L75P
(empty circles) and L174S (ﬁlled triangles) induced by the addition of increasing amounts
of GdnHCl (A), urea (B), or by temperature changes (C). Following excitation at 295 nm,
emission spectra were recorded and curves were obtained by reporting the maximum
emission ﬂuorescence as a function of the denaturing agent concentration value. Trypto-
phan ﬂuorescence intensity as a function of temperature is reported as an inset in C.
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and references therein].
A completely different behavior was observed in the case of L75P-
AApoAI and L174S-AApoAI, as the denaturation curves are shifted to
lower denaturant concentrations compared to wild-type ApoAI,indicating a decreased structural stability. In particular, for L75P-
AApoAI variant (empty circles in Fig. 3 (A–B), protein unfolding was
found not to be a cooperative process and a higher λmax was recorded
even in the absence of the denaturing agent. On the other hand, for
Table 2
Denaturation parameters for the unfolding of AApoAI variants. Data shown are the means from three independent experiments.
Protein D1/2
(M)
ΔGD°
(kcal/mol)
m D1/2
(M)
ΔGD°
(kcal/mol)
m Tm
(°C)
ΔH
(kcal/mol)
GdnHCl Urea Temperature
Wild-type ApoAI 0.90 ± 0.01 2.9 ± 0.5 2.76 ± 0.32 2.1 ± 0.3 4.4 ± 0.4 2.0 ± 0.1 55.3 ± 0.5 26.9 ± 0.1
L75P-AApoAI n.a. n.a. n.a. n.a. n.a. n.a. 40.8 ± 2.2 15.0 ± 0.4
L174S-AApoAI 0.39 ± 0.01 0.20 ± 0.04 0.9 ± 0.2 1.1 ± 0.4 1.3 ± 0.2 1.0 ± 0.2 43.5 ± 4.6 22.4 ± 0.4
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was obtained in the presence of GdnHCl, indicative of a fast and non-
cooperative unfolding process. Following the addition of increasing
amounts of urea, a sigmoidal curve was obtained for L174S variant (Fig.
3B, ﬁlled triangles) even though less pronounced when compared to
the wild-type protein, indicating a loss in unfolding cooperativity. Dena-
turation parameters for the unfolding process of AApoAI variants are re-
ported in Table 2. The lower GdnHCl D1/2 values obtained for wild-type
ApoAI and L174S variant, compared to urea D1/2, may suggest the impor-
tance of electrostatic interactions, efﬁciently weakened by GdnHCl, in the
stabilization of the two proteins [40]. Loss in cooperativity during dena-
turation is a common feature of amyloidogenic variants, as variants
G26R and L178H [18], and the recently published R173P [20] share this
behavior.
Finally, by thermal denaturation (Fig. 3C) we observed that the pro-
teins are all structurally stable up to 50 °C, although enthalpy and mid-
point values, reported in Table 2, were found to be lower for the variants
than for wild-type ApoAI, conﬁrming their lower stability with respect
to the native protein.
3.4. Structural features of wild-type ApoAI, L75P-AApoAI and
L174S-AApoAI: a molecular dynamics study
To address differences in the structural features of the two variants
when compared to the wild-type protein, models of the variants were
obtained and used as inputs for a molecular dynamics (MD) study. In
wild-type ApoAI, L75 is located in the middle of the short helix 70–76
that contributes to deﬁne the relative helical orientation in the four-
segment bundle and interacts with L14 in the “bottom” hydrophobic
cluster formed by V11, L14, F71 and L82. L174, instead, is located in
the packed “bottom” hydrophobic cluster so that its substitution with
Ser was expected to disrupt this cluster [17,22]. On the other hand,
from the MD simulations it emerged that the replacement of L174
with a Ser has only amoderate effect on the overall structure of the pro-
tein. In fact, in the L174S variant, the serine side chain can be well ac-
commodated within the helix 141–180, since it can form a hydrogen
bond with the carbonylic oxygen of Y170 (Fig. 4A). On the contrary,
the L75P substitution has a stronger destabilizing effect, since the pres-
ence of Pro breaks helix 70–76 and disturbs the stabilizing hydrophobic
interactions that play a major role in orienting the helices of the four-
segment bundle (Fig. 4B).
During the MD simulations, no signiﬁcant changes in the overall
structure from the corresponding crystal structure occurred in wild-
type ApoAI, while the two variants show subtle, but signiﬁcant varia-
tions. In particular, the average structures extracted from the trajecto-
ries for the three proteins suggest that L174S-AApoAI, which has an
overall structure similar to that of wild-type protein, presents a slight
reduced radius of gyration (5.91 ± 0.02 nm vs 5.98 ± 0.03 nm of
wild-type ApoAI), while L75P-AApoAI adopts a less compact structure
(+2% in the total solvent accessible surface area), with a signiﬁcant
loss of α-helical content (about−2%). These differences well reﬂect in
the average distances between donor and acceptor atoms involved in
the formation of 310-, α- and π-helices (Table S2). These data are in
overall agreement with those obtained by CD spectra (Fig. 1).
To verify if the conformational changes induced by the mutations
also affects the overall dynamics of the proteins, the trace of thecovariance matrix of CA atoms for the three structures, which is a mea-
sure of the overall ﬂexibility [33], has been evaluated. The values for
wild-type ApoAI, L75P-AApoAI and L174S-AApoAI were 75 nm2,
105 nm2 and 98 nm2, respectively. These data clearly indicate that the
mutations enhance the overall ﬂexibility of the protein.
To obtain a more detailed picture of the observed differences, the
percentage of α-helical content of each residue (helicity) during the
simulationwas plotted as a function of the residue number (Fig. S1). In-
terestingly, although the plots have an overall similar proﬁle for the
three proteins, some differences can be evidenced: wild-type ApoAI is
generally more structured; however in the regions encompassing resi-
dues 18–30, 80–81 and 126–131 it is slightly less structured than the
two variants. L75P-AApoAI shows a lower helical content in correspon-
dence of residues 66–73, 135–137, 157–160 and 172–177, but it is more
structured than bothwild-type ApoAI and L174S in the regions 125–129
and 140–142. L174S-AApoAI has a lower α-helical content in corre-
spondence of residues 107–110, 140–141, but it is more structured in
the regions 77–80 and 158–160. These differences are associated with
slight variations also in the solvent accessible surface area per residue.
Notably, although in the L75P variant the region encompassing residues
135–137 presents a lower helical content when compared to the other
proteins (Fig. S1), it becomes more buried than in L174S-AApoAI and
the wild-type protein, as the average solvent accessible surface area of
residue 136 is: 76, 62 and 76 Å2, in wild-type, L75P-AApoAI and
L174S-AApoAI, respectively.
3.5. Complementary proteolysis experiments
In order to deﬁne ApoAI regions structurally altered by the presence
of mutations, the surface topology of wild-type protein, L75P-AApoAI
and L174S-AApoAI variants was investigated by a complementary pro-
teolysis approach coupled with mass spectrometry identiﬁcation of
cleavage sites (LC–MS) [41]. Complementary proteolysis refers to limit-
ed proteolysis experiments carried out in conditions able to generate a
single proteolytic event on the protein which originates two “comple-
mentary” peptides. Further cleavages occurring on the two complemen-
tary peptides are not considered. Conformational changes induced by
mutations and affecting protein topology were monitored by the ap-
pearance of preferential cleavage sites located in exposed and ﬂexible
regions of the proteins, which become more susceptible to proteolysis
[42,43]. Complementary proteolysis experiments were performed
using trypsin, chymotrypsin and endoprotease Glu-C as conformational
probes. All reactionswere carried out in parallel on the three proteins by
using the same E:S ratio and were monitored on a time-course basis by
sampling the incubationmixture after 15 and 30 min of hydrolysis. Fol-
lowing this time course approach, primary and secondary cleavage sites,
always produced by a single proteolytic event, were only deﬁned on ki-
netic basis. The LC–MS proﬁles showed that both variants were more
susceptible to proteases than the wild-type protein, as demonstrated
by the higher number of peptides released at the same hydrolysis
time (data not shown). This observation suggests that both AApoAI var-
iants are more ﬂexible and/or less structured than the wild-type pro-
tein, in agreement with both spectroscopic and molecular dynamics
data.
The distribution of the proteolytic sites is outlined in Fig. 4C. A sim-
ilar pattern of proteolytic accessibility could be observed in all the
Fig. 4. Structural features of AApoAI variants. A, insight of the structure of helix encompassing residues 141–180 in wild-type ApoAI (yellow) and in L174S variant (cyan). B, ribbon rep-
resentation of the helix bundle in proximity of L75 in the structure of wild-type ApoAI (yellow) and of L75P variant (green). For sake of clarity, one helix from the second chain of the dimer
was removed. C, pattern of preferential proteolytic sites in native and AApoAI variants. Schematic representation of the results obtained from limited proteolysis experiments onwild-type
ApoAI (upper), L75P-AApoAI (middle) and L174S-AApoAI (lower). Proteolytic sites are designed as primary (ﬁlled) or secondary sites (empty) merely on kinetic basis. The R-4 cleavage
site was not taken in consideration, as it is located in the his-tag peptide sequence occurring in the recombinant proteins.
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terminal regions. However, hydrolysis at Y18 and F57 occurred much
faster in the mutants than in wild-type ApoAI and E34 was not recog-
nized in the native protein, suggesting a higher ﬂexibility in the N-
terminal region of the variants. Moreover, cleavage at K96 and Y115,
in L75P- and L174S-AApoAI, respectively, suggests a slight conforma-
tional change in the region including the putative proteolytic site in
AApoAI variants, responsible for the release of the ﬁbrillogenic polypep-
tide. On the contrary, in wild-type ApoAI this region, as reported in the
crystal structure [17], is in a predominantly α-helical structure, which
protects the protein from proteolytic cleavage.
Also at theC-terminus,wild-type ApoAI and L75P variant are charac-
terized by a quite similar proteolytic proﬁle, showing accessibility at
residues R188, Y192 and E223. This region seems to be protected inthe L174S variant, as showed by the disappearance of the E223 cleavage
site and by a slower kinetic of hydrolysis at level of R188 and Y192 res-
idues, thus suggesting that a slight conformational change occurred in
this region. Further differences in the proteolytic patterns of the three
proteins were located in the region encompassing the 131–136 se-
quence that was exposed in the wild-type ApoAI, as demonstrated by
cleavages at R131, K133 and E136. On the contrary, this region became
completely inaccessible in the L75P variant, in perfect agreement with
the molecular dynamics simulation. The accessibility of this sequence
changed also in the L174S variant, where E136 was still recognized,
but with slow kinetics and the appearance of new cleavage sites at
R153 and Y166 was detected. It is noteworthy that these cleavages oc-
curred quite close to the mutation site 174, indicating a higher accessi-
bility of this region, as suggested by molecular dynamics calculations.
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clude that both L75P- and L174S-AApoAI variants have an increased ex-
posure of the N-terminal region.
3.6. Effects of mutations on ApoAI aggregation
As structural and conformational alterations have been associated
with the presence of a single point mutation, the impact of pathogenic
substitutions on the aggregation propensity of full-length AApoAI was
investigated by using different approaches. First, to get information
about the critical concentration [44] of AApoAI variants, proteins were
incubated at different concentrations for 14 days at 37 °C. Their ﬁnal
concentration (cf) was measured spectrophotometrically following the
removal of aggregated species, as described in the Methods section. In
the graph (Fig. S2),we reported 1− cf ./ ci versus ci, where ci is the initial
protein concentration and 1− cf ./ ci is a measure of protein aggregated
species. We calculated a critical concentration of 0.18± 0.05mg/mL for
L75P variant and 0.15 ± 0.04 mg/mL for L174S variant. No aggregation
occurred for the wild-type protein.
Next, wemeasured the kinetics of aggregation of AApoAI variants by
ThT binding assays. Proteins were incubated (0.3 mg/mL) at pH 7.4 in
the presence of ThT, and the increase of ThT emission ﬂuorescence at
482 nm was measured over time (Fig. 5A). A much higher increase in
ThT ﬂuorescence intensity was observed in the case of L174S-AApoAI
variant with respect to L75P-AApoAI, whereas no aggregation of the
wild-type protein was observed, in line with previous results [18]. For
both AApoAI variants, a double-sigmoidal curve of ThT emission was
observed, less evident in the case of L75P-AApoAI variant (inset of Fig.
5A). For both variants, theﬁrst transition occurredwith a smaller ampli-
tude increase in ThT ﬂuorescence intensity with respect to the second
one. The apparent t1/2 values were: 29 ± 9 h and 96 ± 10 h for L75P-Fig. 5. AApoAI aggregation. A, ThT binding assay. Proteins under test were incubated for 144 h
482 nmwere recorded every 60min. A typical curve forwild-type ApoAI (black bold line), L75P-
enlargement of L75P-AApoAI curve. B, apparent hydrodynamic diameter of AApoAI variants ove
variant (empty triangles)were incubated at 37 °C for different length of time. The hydrodynamic
C, D, tapping mode AFM images (height data) of L75P-AApoAI (C) and L174S-AApoAI (D) aggre
sets), 12 nm (D). The insets in C are at the same scale of the background image (inset scan sizeAApoAI and 35 ± 6 h and 83 ± 7 h for L174S-AApoAI. In agreement
with data reported by Grudzielanek and coworkers on insulin aggrega-
tion [45], we hypothesize that the ﬁrst transition is associated to with
the formation of partially folded species able to bind ThT, whereas the
second transition can be due to the formation of amyloid nuclei
(Fig. 5A). Similar results were obtained in the presence of physiological
amount of NaCl (0.15 M). Hence, in our experimental conditions, low
salt concentration has no signiﬁcant effect on the aggregation propensi-
ty of AApoAI variants.
Then, we analyzed the stability of protein tertiary structure upon in-
cubation at 37 °C, as destabilization represents a crucial step during
ﬁbrillogenesis [46]. Proteins were incubated at 37 °C up to 1 week and
at time intervals ANS binding experiments and intrinsic ﬂuorescence
analyses were performed (Fig. S3). In the presence of either
amyloidogenic variants an increase in ANS ﬂuorescence, more evident
for L174S-AApoAI (Fig. S3C, gray line), was detected after 72 h, suggest-
ing conformational changes leading to the exposure of hydrophobic sur-
faces. A decrease in ANS binding was observed after a prolonged
incubation (1 week, Fig. S3C, dashed lines), suggesting shielding of hy-
drophobic patches due to their direct involvement in ﬁbril formation.
No changes in ANS binding was observed instead in the case of wild-
type ApoAI (Fig. S3A). These resultswere conﬁrmed by intrinsic ﬂuores-
cence experiments (Fig. S3D–I and Table S1), showing a decrease of the
emissionmaximum after 72 h incubation to be related to protein aggre-
gation. As a consequence, Trp residues are hindered and remain buried
instead of being exposed to the solvent.
Furthermore, we evaluated the apparent hydrodynamic diameter of
the three proteins bymeans of dynamic light scattering (DLS). For wild-
type ApoAI we obtained an apparent hydrodynamic diameter of 11.0±
1.1 nm, consistent with the size of a protein dimer, as previously report-
ed by X-ray crystallography [22]. The hydrodynamic diameter of theat 25 °C in 50 mM Tris HCl, pH 7.4. During the incubation, emission ﬂuorescence values at
AApoAI (blackﬁne line) and L174S-AApoAI (gray bold line) are shown. The inset shows an
r time.Wild-type ApoAI (empty circles), L75P-AApoAI (empty squares) and L174S-AApoAI
diameter, d(nm), is reported as a function of time, t(days), expressed as logarithmof time.
gates obtained after seven weeks incubation. Scan size 750 nm, Z range 29 nm (C and in-
, 500 nm).
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for the wild-type protein, whereas the L75P-AApoAI variant showed a
diameter of 16.3 ± 0.9 nm, consistent with a less-compact structure
than the native protein, according to intrinsic ﬂuorescence experiments
and MD simulations (Fig. 2B-C). When proteins were analyzed after
24 h incubation, no formation of higher molecular aggregated species
were detected in the three samples, as indicated in Fig. 5B, where the di-
ameter values are plotted as a function of the incubation time. Indeed,
wild-type ApoAI showed a constant apparent diameter up to 7 days
(Fig. 5B) in agreement with ANS binding experiments, intrinsic ﬂuores-
cence analyses and ThT binding (Figs. 2 and 5A), thus conﬁrming no ag-
gregation for the wild-type protein. On the contrary, the variants
showed a different behavior with respect to ApoAI, with peculiar char-
acteristics differentiating one from the other. The apparent diameter
of L174S-AApoAI gradually increased up to 16.9 ± 2.4 nm after 7 days
incubation, whereas L75P-AApoAI reached an apparent diameter value
of 23.6 ± 7.8 nm, suggesting a pronounced decrease of protein com-
pactness over time.
Finally, AFM experiments were performed to inspect the aggregate
morphology after incubation times ranging from 4 to 7 weeks. We
found that L75P-AApoAI formed scanty, short ﬁbrils with length of
200–350 nm and height of 4–6 nm (Fig. 5C). These ﬁbrils exhibit a
beaded morphology, resulting from the assembly of different subunits
of variable size, with not very regular packing. The L174S-AApoAI vari-
ant displayed a higher density of ﬁbrillar aggregates as compared to
L75P-AApoAI. These aggregates were generally smoother, longer and
thinner than those formed by L75P-AApoAI, exhibiting typical lengths
between 200 nm and 4 μm and heights between 1 and 3 nm; Fig. 5D
shows L174S-AApoAI ﬁbrils detected after 7 weeks incubation. In addi-
tion, a minority of thick, beaded ﬁbrils (length 400–500 nm, height 5–
6 nm) was also observed (not shown). No ﬁbrils were detected for
wild-type ApoAI in the same conditions. All the data collected indicate
that the AApoAI variants are prone to aggregate and generate ﬁbrils
qualitatively similar to the ﬁbrillar structures reported in the literature
for other AApoAI variants [18,19].
4. Discussion
Using an array of independent methodologies, the effects of the “in-
side mutation” L75P and the “outside mutation” L174S on ApoAI pro-
pensity to undergo an amyloidogenic pathway have been analyzed
with the aim of elucidating common and different features of
amyloidogenic mutations in the development of the disease. We
found that both variants display: (i) a slightly lower α-helical content
with respect to the native protein and a time dependent increase of β-
strand structure; (ii) more exposed hydrophobic regions, particularly
evident for L174S variant; (iii) reduced stability and loss of unfolding
cooperativity; (iv) increased ﬂexibility; and (v) enhanced susceptibility
to protease cleavage in the N-terminal region.
Nevertheless, the two variants show signiﬁcant differences, which
contribute to add knowledge to the emerging picture of the cause and
effect relationship in ApoAI associated amyloidosis. As supposed, the
substitution of L75 with proline has a destabilizing effect, as it breaks
helix 70–76. This helix overlaps with one of the three predicted N-
terminal amyloid “hot spots”, whose perturbation has been recently
suggested to be a prerequisite for misfolding [21]. This leads to the ex-
posure of hydrophobic residues mainly located in the N-terminal re-
gion, as demonstrated by the increased intrinsic ﬂuorescence intensity
and ANS binding, as well as by the exposure of a proteolytic site at
Y18, belonging to the major hot spot 14–22, as also found for G26R
and L178H variants [18]. Furthermore, the accessibility of further pro-
teolytic sites at E34 and F57 (the latter belonging to the minor hot
spot 53–58), both hindered in the native protein, is the consequence
of the propagation of the local perturbation (helix 70–76) to the other
two predicted hot spots and the cause of the decreased protein com-
pactness. In fact, DLS measurements of the hydrodynamic diameterdemonstrated that the L75P variant is a much less compact protein
with respect to both the wild-type protein and the L174S variant, with
an increased diameter of 50%. Therefore, as a response to the occurrence
of the “internal”mutation L75P, the protein acquires a “looser” structure
at the N-terminal domain, with signiﬁcant alteration of protein confor-
mation and compactness, while the “external” mutation L174S is re-
sponsible for a less destabilized but more ﬂexible structure to which a
more pronounced aggregation-competent state is associated.
In the 3D structure, residue 174 is in close proximity to hot spot 14–
22which appears to be destabilized, as indicated by the appearance of a
cleavage site at Y18. This perturbation could affect thehot spot 53–58, in
line with cleavage at F57. Moreover, in the L174S variant cleavages at
R153 and Y166 occur. The structural differences between L75P- and
L174S-AApoAI variants are mainly due to differences in the exposed re-
gions of the proteins. We believe that in L75P variant the N-terminal re-
gion is more unstructured, as indicated by Trp intrinsic ﬂuorescence
(Fig. 2B) and suggested by DLSmeasurements (Fig. 5B) andMD simula-
tions (Fig. 4B), whereas in L174S the region encompassing residues
153–166 seems to be more unstructured, as demonstrated by limited
proteolysis experiments (Fig. 4C).
We propose that these structural features represent the molecular
basis of the different aggregation propensity of the two variants. Follow-
ing incubation at 37 °C, L174S shows a higher propensity to aggregate
than the L75P variant, as demonstrated by CD and ﬂuorescence analy-
ses, ThT binding and AFM imaging. The time-dependent increase of β-
sheet structure, shown by L75P and L174S variants, is similar to that of
G26R-AApoAI [18], whereas for L178H-AApoAI an increase in the α-
helical content has been described over time, accompanied by the for-
mation of very short ﬁbrillar structures [18]. Upon 7 days incubation
at 37 °C, DLS measurements revealed an over time increase of protein
diameter by about 50% and 44% for the L75P and L174S variants, respec-
tively, compared to the wild-type protein. Noteworthy, L75P-AApoAI
lower compactness well correlates with the beaded morphology of its
ﬁbrils, whereas even though L174S-AApoAI is relatively compact and
less unstructured than the other variant, it presents higher aggregation
propensity than L75P-AApoAI. It is likely that in this case a balance be-
tween protein compactness, partial unfolding, group exposure and ﬂex-
ibility regulates protein amyloidogenicity.
Our data indicate that both amyloidogenic mutations induce protein
destabilization in a region close to themutated residue. The propagation
of the destabilization to the N-terminal hot spots region, allowed by
their proximity in the3D structure, is a sine quanon condition for aggre-
gation, as recently suggested by Das and coworkers [21]. The polymor-
phic behavior observed in our experimental system is not surprising, as
polymorphism is a common feature of amyloid aggregation; in this case
it could be also favored by the direct involvement of the N-terminal re-
gion alone in triggering aggregation, thus resulting in possible multiple
arrangements of the rest of the protein.
Differently from the accepted pathway in which AApoA-I is cleaved
prior to aggregation, Das and coworkers [21] suggested that AApoAI
cleavage canoccur only after aggregationof the full-lengthprotein. There-
fore, aggregation of theN-terminal region of the full-lengthproteinwould
represent the ﬁrst step in the ﬁbrillogenic process. Following the speciﬁc
cleavage of the full-length variant, the formation ofmatureﬁbrils could be
observed. Our observation that L75P- and L174S-AApoA-I are able to ag-
gregate as full-length proteins is consistent with this model, and the
scantiness ofmature ﬁbrils can be explained by the lack of the proteolytic
cleavage. Our ﬁndings highlight a potential key element in the evolution
of the disease, i.e. the partial exposure of K96 and Y115 cleavage sites in
L75P- and L174S-AApoAI, respectively. In fact, in this region, which is
fully hindered in the native protein, the cleavage sites that allow the re-
lease of the ﬁbrillogenic N-terminal polypeptide(s) are expected to be
present. It is tempting to speculate that this region becomes fully exposed
upon aggregation of the full-length variants.
In conclusion, our study adds knowledge, at a molecular level, to the
general mechanism by which amyloidogenic mutations determine
443R. Del Giudice et al. / Biochimica et Biophysica Acta 1860 (2016) 434–444ApoAI systemic amyloidosis, providing a new tessera in the puzzle of
such a severe disease.
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